New drug cocktail aims to wipe out breast cancer before surgery

NCT ID NCT04126525

Ongoing Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial is testing whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can eliminate more cancer in women with HER2-positive early breast cancer. About 53 participants will receive the combination, and the main goal is to see how many have no cancer left at the time of surgery. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pyrotinib (a targeted cancer drug) combined with trastuzumab, paclitaxel, and cisplatin
What this could lead to: If successful, this could offer a more effective pre-surgery treatment for HER2-positive breast cancer, potentially increasing the chance of no cancer remaining at surgery.
What could go wrong: This is a small, early-phase trial with only 53 participants. Results may not apply to all patients, and side effects from the drug combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

female breast carcinoma HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER FEMALE

Contacts and locations

Locations

Renji Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.